Both Ozempic and Mounjaro are approved by the FDA to treat Type 2 diabetes, but some doctors prescribe the medication ...

On Friday, Novo Nordisk A/S (NYSE:NVO) released headline results from part 1 of the ongoing ESSENCE Phase 3 trial, a 240-week ...

People who received weekly injections of semaglutide -- the active agent in the diabetes drug Ozempic and the weight-loss ...

Semaglutide, the scientific name for Novo’s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage ...

A large trial showed that semaglutide, sold as Ozempic for diabetes and as Wegovy for obesity, was better than any current ...

A new study reported in the New England Journal of Medicine found that GLP-1 drugs such as Ozempic and Wegovy which have ...

It is a sign that Novo Nordisk’s efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to ...

Previously, the lowest dose of Wegovy, 25 milligrams, was listed as in short supply. Since early 2022, several doses of semaglutide — the active ingredient in Wegovy and Ozempic — had been on the ...

Novo Nordisk’s Wegovy helped people with a fatty liver disease called MASH experience improvements in liver scarring and achieve symptom resolution, new data show.

The diabetes and weight loss medications Ozempic and Wegovy are now considered to be available after more than two years of ...

Madrigal stock catapulted again Friday after Novo Nordisk published not "game-changing" results for its MASH treatment.

Novo Nordisk’s drug helped reduce knee pain in osteoarthritis patients with obesity. Meanwhile, the Change Healthcare breach ...